HCW Biologics (NASDAQ:HCWB – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($2.83) EPS for the quarter, missing the consensus estimate of ($1.35) by ($1.48), FiscalAI reports. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.12 million. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%.
HCW Biologics Stock Performance
HCW Biologics stock opened at $0.77 on Monday. HCW Biologics has a 1 year low of $0.76 and a 1 year high of $23.94. The company has a market cap of $1.73 million, a PE ratio of -0.03 and a beta of 2.31. The company’s 50-day moving average is $1.52 and its two-hundred day moving average is $3.82.
Analyst Upgrades and Downgrades
HCWB has been the subject of several research reports. Wall Street Zen raised HCW Biologics from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $30.00.
Check Out Our Latest Analysis on HCWB
HCW Biologics Company Profile
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression. HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.
Further Reading
- Five stocks we like better than HCW Biologics
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
